blank
blank

Validation, Publication, and Maintenance of real-world data sources and studies in the HMA-EMA RWD Catalogues

1:1

The purpose of this SOP is to describe the steps and procedures concerning the validation, publication, and maintenance of data sources and studies within the HMA-EMA Catalogues of real-world data (RWD) sources and studies. The principles and activities described will apply specifically to EMA staff responsible for the validation of the Catalogues’ content. The same principles will apply to the Catalogues’ users when submitting entries.

Acces this publication
European Medicines Agency (EMA)

Year of publication

2025

ISBN

SOP/TDA/3543; EMA/467789/2024

Source

European Medicines Agency (EMA)

Author

European Medicines Agency (EMA)

You might also be interested in

uropean Human Genetics Conference (ESHG) 2026

At ESHG 2026 in Gothenburg, ERDERA’s diagnostics work reviewed early progress and the next phase ahead

At the European Human Genetics Conference 2026 in Gothenburg, ERDERA’s Diagnostic Research Workstream reviewed progress, highlighted early results and used a major European genetics meeting to examine how advances in data sharing and genomic analysis may strengthen rare disease diagnosis across countries.
WODC Boston 2026

At World Orphan Drug Congress USA, ERDERA highlights how connected clinical research networks can make rare disease trials more feasible

Boston, 9–11 June 2026: ERDERA's Scientific Coordinator joined the World Orphan Drug Congress USA to set out how stronger clinical research networks can make rare disease trials more feasible across sites and borders.
image (3)

Event Report: 2nd International Conference on Clinical Research Networks (CRNs) for Rare Diseases

The 2nd International Conference on Clinical Research Networks (CRNs), organised by European Rare Diseases Research Alliance (ERDERA), Rare Disease International (RDI) and International Rare Diseases Research Consortium (IRDiRC), brought together the global rare disease community to advance innovative clinical research solutions, with a special focus on low- and middle-income countries (LMICs).
ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.

ERDERA's

search form